Office of Inspector General (OIG) Reports
The Office of the Inspector General (OIG) is an office within the Department of Health and Human Services (DHHS) that is mandated by public law to evaluate the implementation of DHHS programs and report issues of fraud, waste, abuse, and mismanagement.
Medicaid Branded Drugs: Rising Prices Offset by Manufacturer Rebates | August 2011
A report from the OIG assessing changes in prices for brand-name prescription drugs since 2005 and their potential financial impact on the Medicaid program.
View Report
Higher Rebates for Branded Drugs Result in Lower Costs for Medicaid Compared to Medicare Part D | August 2011
A report from the OIG comparing (1) pharmacy reimbursement under Medicare Part D to pharmacy reimbursement under Medicaid for selected drugs, (2) manufacturer rebates under Medicare Part D to manufacturer rebates under Medicaid for selected drugs, and (3) net drug costs under both programs to determine the effect that differences may have on overall program costs.
View Report
Replacing Average Wholesale Price: Medicaid Drug Payment Policy | July 2011
A report from the OIG determining the how States will set reimbursement for Medicaid prescription drugs after First DataBank stops publishing average wholesale prices (AWP) in September 2011.
View Report
Part D Plans Generally Cover Drugs Commonly Used By Dual Eligibles | April 2011
A report from the OIG determining the extent to which formularies used by stand-alone and Medicare Advantage prescription drug plans under Part D include drugs commonly used by full-benefit duals.
View Report
Concerns with Rebates in the Medicare Part D Program | March 2011
A report from the OIG determining the extent to which all Part D sponsors received rebates and passed them on to beneficiaries in 2008.
View Report
FDA’S Approval Status of Drugs Paid for by Medicaid | November 2010
A report from the OIG determining the Food and Drug Administration’s (FDA) approval status of drugs paid for by Medicaid in 2008.
View Report
OIG Releases Work Plan for Fiscal Year 2011 | October 2010
An annual report from the OIG that provides brief descriptions of activities that the OIG plans to initiate or continue with respect to the programs and operations of the DHHS in FY 2011.
View Plan
Drug Manufacturers' Noncompliance with Average Manufacturer Price Reporting Requirements | September 2010
A report from the OIG determining the extent to which drug manufacturers' complied with Average Manufacturer Price (AMP) reporting requirements to CMS as set forth by Federal requirements.
View Report
Invalid Prescriber Identifiers on Medicare Part D Drug Claims | June 2010
A report from the OIG determining the extent to which invalid prescriber identifiers were used on Part D prescription drug event (PDE) records in 2007.
View Report
Comparing Pharmacy Reimbursement: Part D to Medicaid | February 2009
A report from the OIG comparing Medicare Part D and Medicaid pharmacy reimbursement amounts for selected drugs at the national level.
View Report
Role of Nursing Homes and LTC Pharmacies in Assisting Dual-Eligibles with Selecting a Medicare Part D Plan | June 2008
A report from the OIG that reviews the role of nursing homes and LTC pharmacies in assisting dual-eligible residents in selecting a Part D plans. The information was gathered as part of the study, "Availability of Medicare Part D Drugs to Dual-Eligible Nursing Home Residents" (see below).
View Report
Availability of Medicare Part D Drugs to Dual-Eligible Nursing Home Residents
| June 2008
A report from the OIG that focuses on implementation issues that arose in the early stages of the Part D benefit. It is based on interviews with nursing home administrators, medical directors, and directors of operations for LTC pharmacies conducted between September 2006 and March 2007.
View Report
Review of the Relationship Between Medicare Part D Payments to Community Pharmacies and the Pharmacies' Drug Acquisition Costs | January 2008
A report from the OIG that (1) analyzes the relationship between Part D payments, excluding dispensing fees, to community pharmacies and the pharmacies’ drug acquisition costs and (2) estimates Part D dispensing fees and compares them with Medicaid dispensing fees.
View Report
Generic Drug Utilization in the Medicare Part D Program | November 2007
A report from the OIG that determines the extent of generic drug utilization in the Medicare Part D program for the first two quarters of 2006.
View Report
Back to the top